{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:52:47Z","timestamp":1791355967217,"version":"4.3.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00170-1","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:23:36Z","timestamp":1791354216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interest of luspatercept in treatment of anemia in lower-risk of myelodysplastic syndrome anemia: a single center study of 26 patients"],"prefix":"10.1007","volume":"61","author":[{"given":"A.","family":"Elalaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Girault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Cluzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"6","key":"170_CR1","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMp048266","volume":"352","author":"M Cazzola","year":"2005","unstructured":"Cazzola M, Malcovati L. Myelodysplastic syndromes \u2014 coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536\u20138.","journal-title":"N Engl J Med"},{"issue":"20","key":"170_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"6","key":"170_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","volume":"31","author":"P Valent","year":"2007","unstructured":"Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31(6):727\u201336.","journal-title":"Leuk Res"},{"issue":"12","key":"170_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"issue":"4","key":"170_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"RNVS Suragani","year":"2014","unstructured":"Suragani RNVS, Cadena SM, Cawley SM, et al. Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med"},{"issue":"12","key":"170_CR6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","volume":"133","author":"A Piga","year":"2019","unstructured":"Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and transfusion independence in a phase 2 study of patients with beta-thalassemia. Blood. 2019;133(12):1279\u201389.","journal-title":"Blood"},{"issue":"10387","key":"170_CR7","first-page":"1401","volume":"401","author":"U Platzbecker","year":"2023","unstructured":"Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10399):373\u201385.","journal-title":"Lancet"},{"key":"170_CR8","unstructured":"Kyle M. FDA Approves luspatercept as first-line anemia treatment in patients with lower-risk MDS. AJMC. 2023."},{"issue":"2","key":"170_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"8","key":"170_CR10","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","volume":"112","author":"L Zhou","year":"2008","unstructured":"Zhou L, Nguyen AN, Sohal D, et al. Inhibition of transforming growth factor-beta receptor I kinase promotes hematopoiesis in myelodysplastic syndromes. Blood. 2008;112(8):3434\u201343.","journal-title":"Blood"},{"issue":"16","key":"170_CR11","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood.2021011045","volume":"139","author":"M Cazzola","year":"2022","unstructured":"Cazzola M. Ineffective erythropoiesis and its treatment. Blood. 2022;139(16):2460\u201370.","journal-title":"Blood"},{"issue":"10","key":"170_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","volume":"18","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Germing U, G\u00f6tze KS, et al. Luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicenter, open-label phase 2 dose-finding study with long-term extension. Lancet Oncol. 2017;18(10):1338\u201347.","journal-title":"Lancet Oncol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00170-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00170-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00170-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:23:37Z","timestamp":1791354217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00170-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00170-1","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with institutional and national regulations. Ethical approval was obtained from the Ministry of Higher Education and Research (reference AC-2018\u20133110). Because this was a retrospective chart review with anonymized data, individual informed consent was waived according to national guidelines.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"62"}}